Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2016

View Archived Issues

Yisheng completes phase I trial of PIKA hepatitis B vaccine

Taisho Pharmaceutical's TP-0463518 in clinical development for renal anemia

CRISPR/Cas9 gene editing advances, first patient receives cells with edited genes

Oral, ultra-long-acting form of ivermectin achieves sustained therapeutic serum drug concentrations

Chiesi Farmaceutici acquires Atopix Therapeutics

Karolinska Development company raises funds to advance development of GR-3027

Eli Lilly Japan and Torii Pharmaceutical launch Taltz in Japan

BioLineRx inlicenses project for dry eye syndrome

KalVista Pharmaceuticals closes merger with Carbylan

Immunovaccine's DPX-Survivac wins EMA orphan drug designation

ENDURANCE-4 trial shows efficacy of glecaprevir/pibrentasvir in HCV genotypes 4-6

Ability Pharmaceuticals begins phase II study of ABTL-0812

FDA issues complete response letter for Green Cross's IVIG-SN

Enamine and Pcovery extend collaboration

Phase III trial of mepolizumab for eosinophilic granulomatosis with polyangiitis meets endpoints

Gates Foundation grant supports NovoBiotic's work on orally active analogues of teixobactin for TB

Cancer candidate PRI-724 shows antifibrotic potential in patients with HCV and cirrhosis

Farnesoid X receptor agonist LJN-452 well tolerated in first-in-human study

Acorda ends development of dalfampridine to improve post-stroke walking difficulties

FDA grants orphan drug designation to PQR-309

Primary endpoint not met in phase III study of solanezumab for mild dementia due to Alzheimer's

Ruga Corporation changes name to Aravive Biologics

Rgenix patents SLC6A8 inhibitors for cancer

University of Colorado patent reveals beta-lactam antibiotic sensitizers

AstraZeneca describes LTC4 synthase inhibitors

Chiesi Farmaceutici reports compounds for asthma and COPD

Bayer Healthcare divulges TNKS1/TNKS2 inhibitors for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...